FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss
Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the […]